Brief: Spruce Biosciences Provides Clinical Program Updates And Outlook For 2024
04/01/2024 13:58
Jan 4 (Reuters) - Spruce Biosciences Inc SPRB.O :
* SPRUCE BIOSCIENCES PROVIDES CLINICAL PROGRAM UPDATES AND
OUTLOOK
FOR 2024
* TOPLINE RESULTS FROM CAHMELIA-204 IN ADULT CLASSIC CAH
ANTICIPATED IN Q3 2024
* CASH RUNWAY ANTICIPATED INTO FIRST HALF OF 2025
* TOPLINE RESULTS FROM ALL COHORTS IN CAHPTAIN-205 CLINICAL
TRIAL
IN PEDIATRIC CLASSIC CAH PATIENTS IN MARCH 2024
* CASH AND CASH EQUIVALENTS AS OF DECEMBER 31, 2023 WERE
APPROXIMATELY $96 MILLION
* BASED ON COMPANY'S CURRENT OPERATING PLAN, OPERATING AND
CAPITAL
EXPENDITURES ARE FUNDED INTO FIRST HALF OF 2025
Source text for Eikon: ID:nBw8N1NMFa
Further company coverage: SPRB.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Spruce Biosciences
See all newsSpruce Biosciences, Inc. reports results for the quarter ended June 30 - Earnings Summary
Spruce Biosciences Q2 net loss widens on higher expenses
Spruce Biosciences, Inc. expected to post a loss of $5.80 a share - Earnings Preview
Brief: Spruce Biosciences Appoints Adrian Quartel, M.D., Ffpm, As Chief Medical Officer
Brief: Spruce Biosciences Announces Data Presentation At The 18Th International MPS Symposium